Bristol Myers Squibb (BMS) is expanding its computational infrastructure with the deployment of an Nvidia DGX SuperPOD featuring DGX Vera Rubin NVL72 systems. This upgrade enhances BMS’s capabilities in AI-driven drug discovery, allowing for more efficient use of energy and greater performance. The new system will streamline processes, automate target identification, and support various scientific programs across multiple disease areas. BMS aims to integrate AI into its research model, enabling researchers to make more informed decisions and advance drug development effectively. This expansion reflects BMS’s commitment to leveraging AI for improved outcomes in life sciences.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.pharmexec.com/view/bristol-myers-squibb-collaboration-nvidia–ai-
